If you liked this article you might like

Pfizer Finds Breaking Up Is Hard to Do
Sanofi Gains Boost from MS Treatments as Diabetes Drug Lantus Flounders
After FDA Approval, Merck Posts Better-Than-Expected Earnings
What to Watch in Sanofi's Third-Quarter Results